Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Precision Clinical Research, LLC

Neither a doctor nor a teaching hospital

Research payments

$1,420,796

60 payments

Through program year 2025, Precision Clinical Research, LLC is reported as receiving $1,420,796 in research payments, across 60 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $2,112 3
2024 Research $90,656 7
2023 Research $503,408 11
2022 Research $3,750 3
2021 Research $47,391 14
2020 Research $656,405 17
2019 Research $117,073 5

Breakdown

Who paid Research payments · program years 2019–2025
  1. Ironwood Pharmaceuticals, Inc $609,502 24 payments
  2. Novartis Pharmaceuticals Corporation $355,662 1 payment
  3. Novavax Inc $192,779 9 payments
  4. Teva Pharmaceuticals USA, Inc. $143,250 4 payments
  5. Flexion Therapeutics, Inc. $39,417 3 payments
  6. Avion Pharmaceuticals $38,590 4 payments
  7. Exeltis, USA Inc. $22,197 2 payments
  8. Seikagaku Corporation $6,845 1 payment
  9. RedHill Biopharma Inc. $2,200 1 payment
  10. Anika Therapeutics, Inc. $2,150 3 payments
Studies the money was for Research payments · program years 2019–2025
  1. C3718-302 $564,907 17 payments
  2. A Randomized, Four-Arm, Placebo-Controlled, Participant, Investigator and Sponsor-Blinded Study Investigating the Safety, Tolerability and Efficacy of Intra-Articular Canakinumab Followed By Intra-Articular Lna043 in Patients With Knee Osteoarthritis $355,662 1 payment
  3. A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines $192,779 9 payments
  4. A Randomized, Double Blind, Parallel Group, Three Arm, Placebo Controlled, Multi-Site Therapeutic Equivalence Study With Clinical End-points Comparing Test Product "Oxymetazoline Hydrochloride Cream, 1%" to Reference Product "RHOFADETM Cream, 1%" in the Treatment of Moderate to Severe Persistent Facial Erythema of Rosacea $143,250 4 payments
  5. C3718-301 $44,595 7 payments
  6. Randomized, Blinded, 4-Way Crossover Study to Determine the Dosage Form Proportionality, Safety, and Tolerability of 3 Dosage Forms of North Star Desiccated Porcine Thyroid Extract Tablets in Healthy Subjects $40,340 5 payments
  7. A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of FX006 in Patients with Glenohumeral Osteoarthritis or Shoulder Adhesive Capsulitis $21,175 1 payment
  8. A Pivotal, Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, Tolerability ofLPRI-424, 13 Cycles $18,756 1 payment
  9. A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of FX006 in Patients with Hip Osteoarthritis $17,473 1 payment
  10. 6603/1133 $6,845 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record